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Bacterial lipopolysaccharide (LPS), a cell wall component characteristic of Gram-negative
bacteria, is a representative pathogen-associated molecular pattern that allows mammalian
cells to recognize bacterial invasion and trigger innate immune responses.The polysaccha-
ride moiety of LPS primary plays protective roles for bacteria such as prevention from
complement attacks or camouflage with common host carbohydrate residues. The lipid
moiety, termed lipid A, is recognized by the Toll-like receptor 4 (TLR4)/MD-2 complex,
which transduces signals for activation of host innate immunity.The basic structure of lipid
A is a glucosamine disaccharide substituted by phosphate groups and acyl groups. Lipid A
with six acyl groups (hexa-acylated form) has been indicated to be a strong stimulator of
the TLR4/MD-2 complex. This type of lipid A is conserved among a wide variety of Gram-
negative bacteria, and those bacteria are easily recognized by host cells for activation of
defensive innate immune responses. Modifications of the lipid A structure to less-acylated
forms have been observed in some bacterial species, and those forms are poor stimulators
of the TLR4/MD-2 complex. Such modifications are thought to facilitate bacterial evasion
of host innate immunity, thereby enhancing pathogenicity.This hypothesis is supported by
studies of Yersinia pestis LPS, which contains hexa-acylated lipid A when the bacterium
grows at 27˚C (the temperature of the vector flea), and shifts to contain less-acylated forms
when grown at the human body temperature of 37˚C. This alteration of lipid A forms fol-
lowing transmission of Y. pestis from fleas to humans contributes predominantly to the
virulence of this bacterium over other virulence factors. A similar role for less-acylated lipid
A forms has been indicated in some other bacterial species, such as Francisella tularen-
sis, Helicobacter pylori, and Porphyromonas gingivalis, and further studies to explore this
concept are expected.
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PATTERN RECOGNITION OF MICROBIAL COMPONENTS
The invasion of microorganisms into mammalian hosts is ini-
tially sensed by phagocytic cells through their receptors, known
as pattern-recognition receptors (PRRs), to activate the innate
immune response, which is the first line of host defense against
pathogens. Each PRR can recognize a group of microbial compo-
nents having a similar structural pattern, termed the pathogen-
associated molecular pattern (PAMP), and a limited number
of PRRs are enough for surveillance of almost all microbial
pathogens. The toll-like receptor (TLR) family is a representa-
tive PRR family, and different members in this family react with
specific PAMPs (Table 1). In Gram-negative bacteria, PAMPs such
as flagellin, CpG-DNA, and lipopolysaccharide (LPS) are involved
(Figure 1), although flagellin and CpG-DNA are not limited to
Gram-negative bacteria. Flagellin is a protein contained in bac-
terial flagella observed mainly in motile bacteria independent
of Gram-negative or -positive status. CpG-DNA is a term for
unmethylated CpG dinucleotides in a particular base context that
is abundant in bacterial genomic DNA, but rare in mammalian
genomes, and is generally found in both Gram-negative and
-positive bacteria. On the other hand, LPS is a cell wall com-
ponent characteristic of Gram-negative bacteria (Figure 1), but
not of Gram-positive bacteria, and is generally the most potent
immunostimulant among bacterial cell wall components. For
defense against Gram-negative infections in general, LPS is the
most suitable target PAMP for mammalian host cells.
STRUCTURE AND ACTIVITY OF LPS CONSTITUENTS
Lipopolysaccharide consists of a hydrophobic membrane anchor
portion known as lipid A and a non-repeating core oligosaccha-
ride coupled to a distal polysaccharide (O-antigen) that extends
from the bacterial surface (Raetz and Whitfield, 2002). Within this
class of substances, there is an enormous multitude of natural
structural variants that are primarily due to the extended diver-
sity in chemical composition of the polysaccharide region (core
and O-antigen), but also due to considerable variations in the fine
structure of lipid A (Raetz and Whitfield, 2002). In LPS from most
Gram-negative bacteria, the O-specific chain consists of up to 50
repeating oligosaccharide units formed of 2–8 monosaccharide
components in a highly species- and strain-specific manner. In
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Table 1 | PAMPs recognized by the toll-like receptors (TLRs).
TLRs PAMPs Origin of
PAMPs
Reference
TLR1/2 Tri-acylated
lipopeptide
Bacteria,
mycoplasma
Takeuchi et al. (2002)
TLR2 Lipoprotein/
lipopeptide
Gram-positive
bacteria
Aliprantis et al. (1999),
Takeuchi et al. (2000),
Echchannaoui et al. (2002)Peptidoglycan
Lipoteichoic acid
TLR3 Double-stranded
RNA
Virus Edelmann et al. (2004)
TLR4 LPS Gram-negative
bacteria
Poltorak et al. (1998),
Chow et al. (1999),
Hoshino et al. (1999),
Qureshi et al. (1999)
TLR5 Flagellin Flagellated
bacteria
Hayashi et al. (2001), Hawn
et al. (2003)
TLR6/2 Diacyl lipopeptide Mycoplasma Takeuchi et al. (2001)
TLR7 Single-stranded
RNA
RNA virus Kumar et al. (2009)
TLR8 Single-stranded
RNA
RNA virus Kumar et al. (2009)
TLR9 Unmethylated
CpG-DNA
Bacteria
DNA virus
Hemmi et al. (2000), Krieg
(2002)
Lund et al. (2003),
Hochrein et al. (2004), Krug
et al. (2004a,b), Tabeta
et al. (2004)
the vast majority of LPS structures, the O-specific chain is char-
acterized by extremely high structural variability even within a
given bacterial species, which constitutes the chemical basis for the
serological classification of individual wild-type bacterial strains
according to their O-antigenic determinants. Bacterial mutants
having LPS without O-specific chains are able to grow and multi-
ply in vitro, showing that the O-chain in principle is dispensable
for bacterial viability. Based on characteristic colony morphology,
distinct from the smooth (S)-form of wild-type enterobacterial
species, these mutants have been termed as rough (R)-mutants
leading to a corresponding general sub-classification into S- and
R-form LPS. When LPS molecules extracted from any S-LPS-
containing strain are separated by SDS-PAGE, there is extensive
heterogeneity in the size of the molecules due to variations in
the chain length of the O-polysaccharides. This is evident in the
classical “ladder” pattern in SDS-PAGE, where each “rung” up the
ladder represents a lipid A-core molecule substituted with an incre-
ment of one additional O-unit. The spacing between the rungs is
determined by the size of the O-unit.
The primary role(s) of the O-polysaccharides appears to be
protection for bacteria. In animal pathogens, O-polysaccharides
may contribute to bacterial evasion of host immune responses,
particularly the alternative complement cascade. Assembly of the
membrane attack complex is affected by the chemistry of the
O-polysaccharide, its chain length, and the relative amounts of
long chain S-LPS (Rautemaa and Meri, 1999; Murray et al., 2006).
In addition, LPS from some bacteria, such as Helicobacter pylori,
Neisseria gonorrhoeae, N. meningitidis, and Haemophilus influen-
zae, have been found to contain O-antigen structures that closely
resemble human glycosphingolipids due to the presence of com-
mon host carbohydrate residues such as N -acetylneuraminic acid
or l-fucose (Moran et al., 1996). For example, H. pylori, a preva-
lent gastroduodenal pathogen of humans,produces LPS O-antigen
units that can be uniquely decorated by the addition of fucose
residues to generate Lewis antigens, carbohydrates that are also
expressed by the gastric epithelium in humans. Lewis x (Lex)
and Lewis y (Ley) are the dominant Lewis antigens in H. pylori
LPS. Lex is synthesized by the addition of a fucose residue to N -
acetyl-β-lactosamine (LacNAc) units in the O-antigen chains, and
di-fucosylated Ley is synthesized by the addition of a second fucose
residue to Lex. A typical H. pylori O-antigen chain is glycosylated
with multiple internal Lex units and possesses either Lex or Ley at
the terminal position. It has been observed that disease-associated
isolates of H. pylori show a higher tendency to present LPS that
are glycosylated with both Lex and Ley, while the LPS of isolates
obtained from normal mucosa generally present either Lex or Ley
exclusively, or neither (Skoglund et al., 2009). These structures
highly decorated with Lewis antigens have been suggested to be
important for gastric colonization, adhesion, and immune eva-
sion through molecular mimicry where the Lewis antigens provide
a “camouflage” for the bacteria in order to escape the host innate
immune response (Moran, 2008).
The core oligosaccharide has much less structural variation
compared to the hypervariable O-polysaccharides and has limited
variation within a given bacterial genus. Neither the O-antigen
nor the core oligosaccharide is required for the immunostimu-
latory activity of LPS, but rather the lipid A portion is respon-
sible for the activity. A representative type of lipid A is seen in
Escherichia coli, the structure of which is a β-1→6-linked glu-
cosamine disaccharide phosphorylated at the 1 and 4′ positions
and acylated with 6 acyl groups of 12–14 carbon chain lengths
(Figures 1 and 2). This particular type of hexa-acylated lipid A
elicits robust immunostimulatory activity.
Although not secreted by bacterial cells, small amounts of the
LPS are liberated into the medium under some circumstances such
as during cell division. Larger amounts are released by bacteria
killed by antibiotics, phagocytosis, the complement complex, or
treatment with divalent cation chelators. In an infected host, small
amounts of LPS can be protective by stimulating the immune
system, while large amounts induce high fever and lead to septic
shock and death by multiorgan failure and systemic inflammatory
response. LPS liberated from bacteria associates with LPS binding
protein (LBP), an acute phase protein present in the bloodstream
(Schumann et al., 1990), and forms complexes consisting of LPS,
LBP, and soluble CD14 (sCD14) (Tobias et al., 1995). CD14 is
either present in circulation as a sCD14 or is expressed on the
surface of phagocytes as a glycosylphosphatidylinositol (GPI)-
anchored molecule (membrane CD14, mCD14) (Wright et al.,
1990). LPS is delivered from the complexes to mCD14 on the cell
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FIGURE 1 | PAMPs included in Gram-negative bacteria. Flagellin
and CpG-DNA recognized by TLP5 and TLR9, respectively, are found
not only in Gram-negative bacteria but also in Gram-positive bacteria.
On the other hand, LPS recognized by TLR4 is found only in
Gram-negative bacteria as a cell wall component. A hydrophobic
membrane anchor portion of LPS termed lipid A, but not the
polysaccharide portion, is responsible for stimulation of TLR4
signaling. E. coli type hexa-acylated lipid A, relatively conserved
among a wide variety of Gram-negative bacteria, is the most potent
structure that activates the TLR4 pathway.
surface and then transferred to MD-2 for LPS signaling. CD14
does not appear to be essential for LPS responses, but probably
has a role in their amplification (Haziot et al., 1998).
SPECIES DIFFERENCES IN RECOGNITION OF LIPID A
STRUCTURES
Signals for the immunostimulatory activity are transduced into
cells after interaction of LPS (lipid A moiety) with the TLR4/MD-
2 receptor complex that is expressed on the surface membrane of
mammalian cells (Miyake et al., 2000; Miyake, 2004) (Figure 2).
TLR4 is a type I transmembrane molecule containing a large
leucine-rich repeat in the extracellular region where the MD-2
molecule associates. The extracellular domain of TLR4 is not suffi-
cient for LPS recognition, but MD-2 is essential for the recognition
(Shimazu et al., 1999; Akashi et al., 2000; Schromm et al., 2001;
Nagai et al., 2002). MD-2 is a ligand-binding component of the
TLR4/MD-2 complex (Shimazu et al., 1999; Akashi et al., 2000;
Schromm et al., 2001; Nagai et al., 2002), and acyl groups of lipid
A are buried inside a unique hydrophobic cavity of MD-2 (Park
et al., 2009). Binding of lipid A to MD-2 induces dimerization of
TLR4/MD-2 by altering the conformation of the Phe126 surface of
MD-2 and exposing otherwise hidden interaction sites for bind-
ing to the C-terminal domain of the second TLR4 molecule. It has
been suggested that dimerization of the extracellular domains of
TLR4 leads to proper orientation of the intracellular TIR domains,
recruitment of adaptor proteins, and initiation of intracellular
signaling (Jin and Lee, 2008) (Figure 2).
In naturally isolated lipid A preparations, heterogeneous lipidic
materials and minor contaminants that may influence the activity
are involved. To avoid such possible influences, chemically synthe-
sized diverse lipid A structures are used for studies of structure-
activity relationships, and the lipid A structure of the E. coli type
(Figure 2) has been found to be the most potent immunostimula-
tor (Galanos et al., 1985; Homma et al., 1985; Kotani et al., 1985).
These studies indicate that the number and carbon chain length of
acyl groups attached to the phosphorylated glucosamine backbone
are critical for TLR4 activation, and that alteration of these fac-
tors can reduce the magnitude of the activation (Schromm et al.,
2000; Kusumoto et al., 2003). Moreover, it has also been found that
the response of human cells to such altered structures is stricter
than that of mouse cells (Golenbock et al., 1991; Matsuura et al.,
1999). For example, E. coli type hexa-acylated lipid A (synthetic
compound 506) acts as a strong TLR4 agonist to both human and
mouse macrophages, while tetra-acylated lipid IVa (synthetic com-
pound 406) acts as an agonist to mouse macrophages, although the
activity is weaker than that of compound 506, and as an antagonist
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FIGURE 2 | Differential recognition of lipid A structures between
human and mouseTLR4/MD-2 complexes. TLR4 is a type I
transmembrane molecule, and MD-2 is an extracellular molecule that
associates with the extracellular region of TLR4. Lipid A can bind to
MD-2 but not to TLR4. Binding of lipid A to MD-2 induces dimerization
of the TLR4/MD-2 complex for transduction of stimulatory signals into
cells. Recognition of lipid A structures by mouse MD-2 and human
MD-2 is different. For example, E. coli type hexa-acylated lipid A is
recognized as a strong agonist by both mouse and human MD-2 that
causes dimer formation. On the other hand, tetra-acylated lipid IVa can
bind to both types of MD-2, but subsequent dimer formation is
achieved only by the mouse system and not by the human system.
Once this structure binds to human MD-2, dimer formation is
suppressed, and as a result, this structure acts as an antagonist.
(suppressor to agonist) to human macrophages (Figure 2). Lipid
IVa is a structure identified as a biosynthetic precursor of lipid
A. Lipid IVa binds to both mouse and human MD-2, whereas it
induces dimerization of the mouse TLR4/MD-2 complex, but not
of the human TLR4/MD-2 complex (Akashi et al., 2001; Saitoh
et al., 2004). Some amino acid residues are not conserved between
human and mouse TLR4/MD-2 molecules. These include amino
acid residues of MD-2, like the hydrophobic residues (Leu125 and
Pro127) in the Phe126 loop of mouse MD-2 (corresponding to
human Lys125 and Ser127, respectively), and amino acids of TLR4,
like Lys367 and Arg434 located near the dimerization interface
of mouse TLR4 (corresponding to human Glu369 and Gln436,
respectively), that are suggested to participate in the dimerization
of mouse TLR4/MD-2 mediated by lipid IVa (Ohto et al., 2012).
VARIATION OF LIPID A STRUCTURES
Among natural lipid A, the hexa-acylated E. coli type is relatively
conserved in a wide variety of Gram-negative bacteria, although
some bacterial species have different types of lipid A. Even in a sin-
gle species of bacteria, some variants of lipid A frequently coexist
and their structures are sometimes modified under different envi-
ronmental conditions (Raetz and Whitfield, 2002). A variety of
human pathogens, including Yersinia pestis and Francisella tularen-
sis, have lipid A moieties that are poorly recognized by the human
TLR4/MD-2 complex (Kawahara et al., 2002; Vinogradov et al.,
2002; Phillips et al., 2004). These lipid A species typically consist
of only four or five acyl groups, some of which are 16–18 carbons
in length. It is known that LPS-hyporesponsive mice (C3H/HeJ),
which have a dysfunctional mutant TLR4, are highly susceptible to
infection with Gram-negative bacteria (O’Brien et al., 1982; Vogel
et al., 1999). This implies that the potential for those pathogens to
cause severe disease in humans is likely attributable to their weak
lipid A activity for TLR4 signaling.
VIRULENCE FACTORS IN RELATION TO Y. PESTIS INFECTION
Y. pestis is the causative agent of plague in humans and is primarily
a rodent pathogen that is transmitted to humans through the bite
of an infected flea (Perry and Fetherston, 1997). The temperature
range for a flea residing in rodent burrows or mammalian hair is
around 25˚C,while the body temperature of rodents and humans is
around 37˚C. In the infection cycle of Y. pestis, this bacterium sur-
vives in two different temperature environments in which various
bacterial cellular components are differently expressed (Brubaker,
1991; Straley and Perry, 1995; Anisimov et al., 2004). The pro-
duction of several virulence factors, such as the fraction 1 antigen
(Du et al., 2002), the pH 6 antigen (Huang and Lindler, 2004),
Yop proteins (Viboud and Bliska, 2005), and the type III secretion
system (Cornelis, 2002), are upregulated during growth of the
bacterium at 37˚C. In contrast, the production of murine toxin
(Hinnebusch et al., 2002), which is required for the survival of
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the bacterium in the midgut of fleas, is synthesized at 27˚C and is
downregulated at 37˚C. Structural changes of lipid A in the bac-
terium between those two different temperature ranges have also
been found based on MALDI-TOF mass spectrometric analysis
(Kawahara et al., 2002). The lipid A present in LPS of the bac-
terium is heterogeneous (from hexa- to tri-acylated types) when
it is grown at 27˚C, and shifts to the hypo-acylated types (tetra-
and tri-acylated types) when it is grown at 37˚C. LPS isolated from
Y. pestis grown at 37˚C has been revealed to exhibit much weaker
stimulation activity of human macrophages for proinflammatory
cytokine production than that from the bacterium grown at 27˚C
(Montminy et al., 2006; Matsuura et al., 2010). Such a shift of lipid
A structures to hypo-acylated types probably weakens the bac-
terial ability to stimulate TLR4 signaling and facilitates bacterial
evasion of host innate immunity, allowing free growth in the host
and thereby enhancing bacterial virulence. This infection strat-
egy of Y. pestis seems to play an important role, since the bacteria
need to achieve remarkable multiplication rates after inoculation
of only a few bacteria in the skin delivered by a flea bite to develop
bubonic plague. A genetically modified strain of Y. pestis (KIM5-
pLpxL strain) expressing a potent TLR4-activating hexa-acylated
lipid A at 37˚C has been prepared, and the strain is unable to cause
systemic disease in wild-type mice, despite the presence of other
well-established virulence factors (Montminy et al., 2006). In addi-
tion, the administration of TLR4 agonists has been demonstrated
to augment host defense against lethally high doses of Y. pestis in
a mouse pneumonic plague model (Airhart et al., 2008). These
studies indicate that the ability to evade TLR4 activation by lipid
A alteration is critical for Y. pestis virulence.
ROLE OF LIPID A ALTERATION DURING Y. PESTIS INFECTION
As mentioned above, the scheme summarized in Figure 2 was
obtained from an analysis of the structure-activity relationship
using chemically synthesized lipid A analogs. In studies of Y. pestis,
LPS preparations isolated from bacteria grown at 27 or 37˚C by the
conventional phenol-water extraction method are used. Chem-
ical analysis of these natural LPS preparations reveals that LPS
at 27˚C contains a mixture of lipid A from hexa- to tri-acylated
types, and LPS at 37˚C a mixture of only tetra- and tri-acylated
types (Kawahara et al., 2002). The abilities of such LPS prepa-
rations to stimulate mouse and human macrophages have been
investigated, and results clearly show that LPS at 27˚C exhibits
strong agonistic activity to both mouse and human macrophages,
while LPS at 37˚C exhibits agonistic activity to mouse macrophages
(although weaker than that of LPS at 27˚C), but antagonistic activ-
ity to human macrophages (Matsuura et al., 2010). These results
indicate that LPS at 27˚C and LPS at 37˚C behave just like hexa-
acylated lipid A and tetra-acylated lipid A as shown in Figure 2,
respectively. It is believed that LPS is not easily released from bacte-
rial cell walls without lysis or the destruction of bacterial cells, and
the behavior of bacterium-bound LPS rather than bacterium-free
LPS is considered to be more important for investigating the role of
LPS during bacterial infections. To evaluate the role of bacterium-
bound LPS, formalin-killed bacteria (FKB) have been prepared
from Y. pestis grown at 27 or 37˚C, and their ability to stimulate
human macrophages has been examined (Matsuura et al., 2010).
FKB grown at 27˚C strongly stimulates human macrophages for
proinflammatory cytokine production, similar to LPS at 27˚C. This
activity is substantially suppressed in the presence of an anti-TLR4
antibody, indicating that the LPS-TLR4 signaling pathway plays a
dominant role in reacting to whole bacterial cells among the path-
ways mediated by various bacterial cell components. In contrast,
FKB grown at 37˚C shows no antagonistic activity, unlike LPS at
37˚C, but instead exhibits weak agonistic activity that is probably
dependent on bacterial components other than LPS. This sug-
gests that for antagonistic activity, but not for agonistic activity,
LPS is required to be free from bacterial cells. Taken together, the
important role of lipid A alteration in the infection cycle of Y.
pestis is understood as summarized in Figure 3. Y. pestis grown
at 37˚C has LPS-containing hypo-acylated lipid A species that
act as partial agonists to mouse cells, but act as neither agonists
nor antagonists to human cells. Upon infection with Y. pestis, the
mouse innate immune system responds to some extent, but not
so strongly as to completely eliminate the bacteria, leading to the
prolonged presence of a moderate amount of bacteria. As a result,
the mouse is a reservoir of Y. pestis. On the other hand, the human
innate immune system cannot respond to the bacteria at all, even
though TLR4 signaling is not suppressed. As a result, Y. pestis
grows freely in the human body and induces severe diseases such as
bubonic, septicemic, and pneumonic plague. Recently, transgenic
mice expressing human rather than mouse TLR4/MD-2 have been
generated to test whether the blunted recognition of hypo-acylated
LPS by the human receptor complex dictates susceptibility to infec-
tion of Y. pestis (Hajjar et al., 2012). These “humanized” mice are
indeed more sensitive to Y. pestis infection than wild-type mice,
supporting the idea that evasion of recognition by TLR4/MD-2
promotes Y. pestis virulence in humans.
PATHOGENIC YERSINIA AND LIPID A
The biosynthesis of lipid A and its modification has been inten-
sively studied using E. coli (Raetz et al., 2007). The final steps of
lipid A synthesis occur in the inner membrane, where two acyl
groups are added to the tetra-acylated keto-deoxyoctulosonate
(Kdo)-lipid IVa before the mature hexa-acylated lipid A is exported
to the outer membrane. Kdo is a sugar component found in all
known core oligosaccharide species of LPS. The late acyltrans-
ferases HtrB (LpxL) and MsbB (LpxM) consecutively add lauroyl
(C12) and myristoyl (C14) groups to the tetra-acylated interme-
diate (Clementz et al., 1996, 1997; Somerville et al., 1996). In Y.
pestis, homologs of the late acyltransferase genes, lpxP and lpxM,
have been identified (Rebeil et al., 2006). LpxP acts instead of
LpxL to add a palmitoleate (C16:1) to the 3-hydroxy myristoyl (3-
OH C14) group substituting at the 2′ position of the glucosamine
disaccharide backbone. Expression of these genes in Y. pestis has
been revealed to be suppressed at 37˚C while upregulated at 27˚C
(Figure 3). Through this study, the underlying mechanism for
temperature-dependent alteration of the Y. pestis lipid A structure
has been clarified. In addition to Y. pestis, two more important
human pathogens are included in the genus Yersinia, Y. pseudotu-
berculosis, and Y. enterocolitica. These three species of bacteria have
been cultured at 21 and 37˚C to analyze the structural differences of
the lipid A forms between them (Rebeil et al., 2004). After growth
at 37˚C, each of these species synthesizes LPS-containing mainly
tetra-acylated forms of lipid A, and shifts to increased acylation of
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FIGURE 3 | Infection cycle ofY. pestis and temperature-dependent
alteration of its lipid A structures.Y. pestis, a causative agent of plague,
grows in mice at 37˚C by possessing a tetra-acylated type as its major lipid
A species. This lipid A species acts as a partial agonist to mouse cells, and
Y. pestis is recognized by the mouse innate immune system to some
extent but not enough to eliminate it completely. As a result, moderate
amounts of the bacteria can survive in mice for a prolonged period, and
infected mice serve as a reservoir ofY. pestis. Through flea bites, this
bacterium moves into fleas and grows actively at 27˚C, its optimal growth
temperature. At this temperature, expression of the late acyltransferase
genes (lpxM and lpxP ) is upregulated, and a hexa-acylated type becomes
predominant among its lipid A species. Then, the bacterium moves into a
human body through the bite of an infected flea and grows at 37˚C. At this
temperature, the expression of the late acyltransferase genes is
downregulated, and the major lipid A species shift to the tetra-acylated
type.Y. pestis containing such lipid A species is not sensed (is silent) by
the human TLR4-mediated innate immune system, and the bacteria can
grow freely and induce severe diseases.
lipid A to hexa-acylated forms at 21˚C, although some differences
are seen in the number and type of acyl groups between each
species. Moreover, LPS preparations from these species grown
at 21˚C have been confirmed to strongly stimulate human cells,
while those at 37˚C do not. In contrast to Y. pestis, which causes
highly invasive and usually lethal infections, Y. pseudotuberculosis
and Y. enterocolitica cause relatively mild food- and water-borne
gastroenteritis; however, the temperature changes during their
infection cycles from lower temperatures (external environment
or flea) to higher temperatures (mammalian body) are similar.
These results suggest that the production of a less immunostim-
ulatory form of LPS upon entry into the mammalian host is a
conserved pathogenesis mechanism in the genus Yersinia.
BACTERIA WITH LESS-ACYLATED LIPID A
Francisella tularensis, a causative agent of zoonotic tularemia, con-
tains LPS with less-acylated lipid A. The major lipid A molecule in
this bacterium is reported to be a monophosphoryl tetra-acylated
lipid A with three 3-OH C18 acyl groups and one C16 acyl group
(Vinogradov et al., 2002; Phillips et al., 2004). LPS isolated from
this bacterium shows neither agonistic activity nor antagonistic
activity to TLR4 signaling in either human or mouse cells (Hajjar
et al., 2006). These so-called silent characteristics of F. tularensis
LPS are thought to contribute to its capacity to evade mam-
malian immune defense mechanisms and to promote survival in
an infected host (Sjostedt, 2006; Gallagher et al., 2007). The effect
of the preventive administration of a synthetic TLR4 agonist on the
protection of mice from experimental pneumonic tularemia has
been demonstrated (Lembo et al., 2008). Considering this result,
together with the protective effect of TLR4 agonists against lethal
infection of Y. pestis in a mouse model (as mentioned above), pro-
phylactic administration of TLR4 stimulating agents may be useful
for the prevention of infectious diseases caused by pathogens that
evade TLR4-mediated host innate immunity.
H. pylori produces LPS with unique structures, not only in
its O-antigen region (as mentioned above) but also in its lipid
A region. It is well known that H. pylori lipid A shows up to
1,000-fold weaker activity when stimulating TLR4 than does E.
coli lipid A (Mandell et al., 2004). Therefore, it is thought that
the LPS structure of H. pylori has evolved to aid the bacterium
in evading the host innate immune system, thereby contributing
to chronic infection. The major lipid A species in LPS of this bac-
terium is a tetra-acylated type; however, the process to produce this
lipid A species is different from that of Y. pestis. In H. pylori, the
hexa-acylated lipid A species is first synthesized, and then several
modification enzymes, including a deacylase, function to produce
the tetra-acylated lipid A species (Stead et al., 2008).
Porphyromonas gingivalis is considered to be an important
agent in human periodontal diseases. The LPS of this bacterium
contains highly variant lipid A species: in addition to di- and
mono-phosphorylated and penta- and tetra-acylated species, non-
phosphorylated species are also present (Rangarajan et al., 2008;
Coats et al., 2009). It is believed that the LPS of this bac-
terium, which contains various lipid A species with weak agonistic
and strong antagonistic activities to TLR4 signaling, is a critical
virulence factor to evade the host innate defense system.
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CONTRIBUTION OF LIPID A ALTERATION TO LIVE BACTERIAL
REACTIONS
Most of the above mentioned studies have investigated the activity
of isolated LPS preparations having less-acylated lipid A species.
However, the contribution of their activity to the direct interaction
of live bacteria with host mammalian cells, especially with human
cells, during infection has not been well studied. To address this
issue, mutant strains of Salmonella enterica serovar typhimurium
(S. typhimurium) having fewer lipid A acyl groups (penta- and/or
tetra-acylated types) have been established. These mutants have
been used to infect human cells to investigate their stimulatory
activity (Matsuura et al., 2012). The stimulatory activity of live
bacteria on human cells disappears suddenly when only one acyl
group of lipid A is eliminated from that of the wild-type strain,
from a hexa- to a penta-acylated lipid A type. The antagonistic
activity on TLR4 signaling observed in less-acylated LPS disap-
pears in the live bacterial reaction, as is the case with FKB of Y.
pestis grown at 37˚C, indicating that the antagonistic activity of
LPS is unable to be displayed in whole cell reactions. This study
demonstrated that the important role of less-acylated lipid A in
live bacteria is to present a silent, but not antagonistic, state to
TLR4 signaling.
MODIFIED LIPID A IN CLINICAL ISOLATES
It has been found that a surprisingly large fraction of meningococ-
cal isolates have LPS with under-acylated (penta-acylated) lipid A
as a result of a mutation of the lpxL gene (Fransen et al., 2009),
which likely arises spontaneously in hosts. This finding revealed
the important pathogenic role of lipid A modification in a par-
ticular infectious disease. Findings of similar LPS mutants among
clinical isolates of other infectious diseases are expected, since such
investigations have rarely been carried out before now.
FUTURE PERSPECTIVES
Data are accumulating to support the idea that modification of
lipid A structures to less-acylated species leads to bacterial evasion
of host innate immunity. However, most of these studies have
been carried out by using chemically synthesized compounds or
isolated LPS preparations, but usually not with whole bacter-
ial cells, especially live bacteria. The data indicating differential
behavior of bacterium-bound LPS with less-acylated lipid A com-
pared to bacterium-free LPS, and that show a dominant role
of the LPS-TLR4 signaling pathway among the pathways medi-
ated by various bacterial cell components, have been obtained
from experiments using whole bacteria as described above. LPS-
altering mutants can be associated with changes in other bac-
terial virulence determinants, and it is important to understand
how these factors interact with each other to cause detrimen-
tal effects on the host in practical disease situations. Infection
experiments using living bacteria will improve our understand-
ing of the underlying mechanisms of how other factors asso-
ciate with lipid A alterations in the induction of infectious
diseases.
Species differences in the specificity of the interaction of
TLR4/MD-2 with LPS prevent generalization to humans from
mouse disease models, the most extensive sources of evidence
to date. To overcome this problem, transgenic mice expressing
human TLR4/MD-2 have been generated recently, as described
above. Such humanized mice, not only for TLR4/MD-2 but
also for other molecules that participate in infectious diseases,
are potentially strong tools for practically analyzing the roles of
lipid A alteration in human infectious diseases. For the devel-
opment of protective and therapeutic agents against infectious
diseases, humanized mice can also be used to test efficacy. In
particular, when evaluating the safety of TLR4 agonistic agents,
humanized mice may play an important role since humans
are more sensitive to the endotoxic activity of LPS than are
mice.
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